Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06866418 · ClinicalTrials.gov registry record
Phagenyx® Registry Study
A clinical trial of Dysphagia, sponsored by Phagenesis.
- Recruiting
- Registry status
- 600
- Enrollment target
- 2
- Study locations
NCT06866418: Recruiting study of Dysphagia, sponsored by Phagenesis.
NCT06866418 is a study of Dysphagia that is actively recruiting participants, run by Phagenesis. The registered enrollment target is 600 participants, above the 155-participant average among 35 other Dysphagia trials with a reported enrollment target (287% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06866418, a study of Dysphagia, is actively recruiting participants, sponsored by Phagenesis.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 2
- Study locations
Study Summary
A retrospective, open-label, matched-control registry study designed to characterize the effectiveness of Pharyngeal Electrical Stimulation (PES) to improve swallowing in patients with severe dysphagia post stroke when delivered using the Phagenyx® System in real-world clinical settings in hospitals in the United States of America (US).
Primary Outcome
Swallowing safety based on the change in Penetration Aspiration Scale (PAS) score from baseline (pre-PES treatment) to 2 (+1 days) post PES treatment.
Conditions Studied
Interventions
- DEVICE 1. Phagenyx® System Group Patients
Study Locations (2)
New Jersey
- HMH Jersey Shore University Medical Center - Neptune City
Texas
- University of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2036-09 |
What NCT06866418 shows while recruiting
NCT06866418 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 155-participant average among 35 other Dysphagia trials with a reported enrollment target (287% higher).
The record links to 1 condition, with Dysphagia appearing as the primary indexed condition, and to 1 intervention - of which 1. Phagenyx® System Group Patients is the first listed.
NCT06866418 reports a single indexed study location in New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT06866418 about?
NCT06866418 is a clinical study titled "Phagenyx® Registry Study". A retrospective, open-label, matched-control registry study designed to characterize the effectiveness of Pharyngeal Electrical Stimulation (PES) to improve swallowing in patients with severe dysphagia post stroke when delivered using the Phagenyx® System in real-world clinical settings in hospitals...
What is the current status of trial NCT06866418?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2025-09-15. Estimated completion is 2036-09.
What conditions does trial NCT06866418 study?
This clinical trial studies the following conditions: Dysphagia.
What interventions are being tested in trial NCT06866418?
The interventions under investigation include: 1. Phagenyx® System Group Patients (DEVICE).
Who is sponsoring clinical trial NCT06866418?
This trial is sponsored by Phagenesis, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06866418 being conducted?
This trial has 2 study locations across New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dysphagia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06866418's enrollment target sits among peer trials
600 3rd of 35 higher than 33 of 35 other Dysphagia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dysphagia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
Dissemination and Implementation of DIGEST™ as an Evidence-based Measurement Tool for Dysphagia: A Randomized Implementation Trial
RECRUITING · NA
-
Effect of Thickened Feeds on Swallow Physiology in Children With Dysphagia
RECRUITING · NA
-
Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study
RECRUITING · NA
-
Evolution of the Chicago Classification: Bridging Physiology and Mechanics
RECRUITING · NA
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI